October 4, 2021 -- Thermo Fisher Scientific recently assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland, the company announced.
The new site is part of the company's strategic partnership with CSL Limited, which was announced last year. It will become part of Thermo Fisher's global biologics manufacturing network, and approximately 200 employees will join the company.
The Lengnau site, which is expected to be completed in 2022, is a 1.5 million-sq-ft facility that will leverage bioproduction technologies, including both single-use and stainless steel, with up to a 12,500L bioreactor capacity.
Thermo Fisher will initially support manufacturing of CSL's Idelvion for patients with hemophilia B. The company plans to expand the use of the site in the future to include additional biopharma customers.